Epithelial Cell Adhesion Molecule (EpCAM) Regulates HGFR Signaling to Promote Colon Cancer Progression and Metastasis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Aug 5

PMID 37543570

Authors

Chi-Chiu Lee

Chia-Jui Yu

Sushree Shankar Panda

Kai-Chi Chen

Kang-Hao Liang

Wan-Chen Huang

Yu-Shiuan Wang

Pei-Chin Ho

Han-Chung Wu

Affiliations

Soon will be listed here.

Abstract

Background: Epithelial cell adhesion molecule (EpCAM) is known to highly expression and promotes cancer progression in many cancer types, including colorectal cancer. While metastasis is one of the main causes of cancer treatment failure, the involvement of EpCAM signaling in metastatic processes is unclear. We propose the potential crosstalk of EpCAM signaling with the HGFR signaling in order to govern metastatic activity in colorectal cancer.

Methods: Immunoprecipitation (IP), enzyme-linked immunosorbent assay (ELISA), and fluorescence resonance energy transfer (FRET) was conducted to explore the extracellular domain of EpCAM (EpEX) and HGFR interaction. Western blotting was taken to determine the expression of proteins in colorectal cancer (CRC) cell lines. The functions of EpEX in CRC were investigated by proliferation, migration, and invasion analysis. The combined therapy was validated via a tail vein injection method for the metastasis and orthotopic colon cancer models.

Results: This study demonstrates that the EpEX binds to HGFR and induces downstream signaling in colon cancer cells. Moreover, EpEX and HGF cooperatively mediate HGFR signaling. Furthermore, EpEX enhances the epithelial-to-mesenchymal transition and metastatic potential of colon cancer cells by activating ERK and FAK-AKT signaling pathways, and it further stabilizes active β-catenin and Snail proteins by decreasing GSK3β activity. Finally, we show that the combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.

Conclusion: Our findings illuminate the molecular mechanisms underlying EpCAM signaling promotion of colon cancer metastasis, further suggesting that the combination of EpAb2-6 and crizotinib may be an effective strategy for treating cancer patients with high EpCAM expression.

Citing Articles

The Olive Oil Phenolic -(-)-Oleocanthal Suppresses Colorectal Cancer Progression and Recurrence by Modulating SMYD2-EZH2 and c-MET Activation.

Tarun M, Elsayed H, Ebrahim H, El Sayed K Nutrients. 2025; 17(3).

PMID: 39940255 PMC: 11821053. DOI: 10.3390/nu17030397.

Intracellular domain of epithelial cell adhesion molecule induces Wnt receptor transcription to promote colorectal cancer progression.

Panda S, Lee C, Geevimaan K, Chen K, Yang S, Shen C J Biomed Sci. 2024; 31(1):72.

PMID: 39010070 PMC: 11247908. DOI: 10.1186/s12929-024-01057-y.

Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.

Zhang X, Wang X, Wen Y, Chen S, Zhou C, Wu F Clin Transl Med. 2024; 14(4):e1649.

PMID: 38629624 PMC: 11022306. DOI: 10.1002/ctm2.1649.

Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.

MacLean M, Walker O, Arun R, Fernando W, Marcato P Int J Mol Sci. 2024; 25(7).

PMID: 38612911 PMC: 11012648. DOI: 10.3390/ijms25074102.

The Predictive Value of Neutrophil Extracellular Trap-Related Risk Score in Prognosis and Immune Microenvironment of Colorectal Cancer Patients.

Dong J, Zhao J, Wu Z, Liu J, Wang B, Qi X Mol Biotechnol. 2024; .

PMID: 38580851 DOI: 10.1007/s12033-024-01135-4.

References

Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M . Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009; 11(2):162-71. DOI: 10.1038/ncb1824. View

Lu T, Lu R, Liao M, Yu J, Chung C, Kao C . Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem. 2010; 285(12):8719-32. PMC: 2838295. DOI: 10.1074/jbc.M109.077081. View

Gires O, Pan M, Schinke H, Canis M, Baeuerle P . Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?. Cancer Metastasis Rev. 2020; 39(3):969-987. PMC: 7497325. DOI: 10.1007/s10555-020-09898-3. View

Lin C, Liao M, Lin W, Wang Y, Lu T, Wu H . Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem. 2012; 287(47):39449-59. PMC: 3501065. DOI: 10.1074/jbc.M112.386235. View

Liang K, Tso H, Hung S, Kuan I, Lai J, Ke F . Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett. 2018; 433:165-175. DOI: 10.1016/j.canlet.2018.06.040. View

Chen H, Liang K, Lai J, Lan C, Liao M, Hung S . EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway. Cancer Res. 2020; 80(22):5035-5050. DOI: 10.1158/0008-5472.CAN-20-1264. View

Liao M, Lai J, Yen-Ping Kuo M, Lu R, Lin C, Cheng P . An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget. 2015; 6(28):24947-68. PMC: 4694806. DOI: 10.18632/oncotarget.4453. View

Lai A, Abella J, Park M . Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009; 19(10):542-51. DOI: 10.1016/j.tcb.2009.07.002. View

Koch J, Aebersold D, Zimmer Y, Medova M . MET targeting: time for a rematch. Oncogene. 2020; 39(14):2845-2862. DOI: 10.1038/s41388-020-1193-8. View

10.

Li Z, Yanfang W, Li J, Jiang P, Peng T, Chen K . Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 2018; 432:237-250. DOI: 10.1016/j.canlet.2018.04.035. View

11.

Cao L, Wang F, Li S, Wang X, Huang D, Jiang R . PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. Cancer Lett. 2018; 444:116-126. DOI: 10.1016/j.canlet.2018.12.015. View

12.

Garcia-Vilas J, Medina M . Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol. 2018; 24(33):3695-3708. PMC: 6127652. DOI: 10.3748/wjg.v24.i33.3695. View

13.

Lin Y, Lu C, Hsiang Y, Pi S, Chen C, Cheng K . c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells. J Cell Physiol. 2018; 234(7):10336-10344. DOI: 10.1002/jcp.27701. View

14.

Brabletz T, Kalluri R, Nieto M, Weinberg R . EMT in cancer. Nat Rev Cancer. 2018; 18(2):128-134. DOI: 10.1038/nrc.2017.118. View

15.

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

16.

Hsu Y, Osmulski P, Wang Y, Huang Y, Liu L, Ruan J . EpCAM-Regulated Transcription Exerts Influences on Nanomechanical Properties of Endometrial Cancer Cells That Promote Epithelial-to-Mesenchymal Transition. Cancer Res. 2016; 76(21):6171-6182. PMC: 5405773. DOI: 10.1158/0008-5472.CAN-16-0752. View

17.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello M . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2005; 366(1):2-16. DOI: 10.1016/j.gene.2005.10.018. View

18.

Tang Z, Du R, Jiang S, Wu C, Barkauskas D, Richey J . Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2009; 99(6):911-22. PMC: 2538758. DOI: 10.1038/sj.bjc.6604559. View

19.

Schnell U, Kuipers J, Giepmans B . EpCAM proteolysis: new fragments with distinct functions?. Biosci Rep. 2013; 33(2):e00030. PMC: 3601740. DOI: 10.1042/BSR20120128. View

20.

An P, Chen F, Li Z, Ling Y, Peng Y, Zhang H . HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3β/Snail signals. Oncogene. 2020; 39(26):4956-4969. DOI: 10.1038/s41388-020-1337-x. View